Intec Parent

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.

Implied Volatility Surging for Intec Pharma (NTEC) Stock Options

JERUSALEM, May 28, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will present at the Jefferies Virtual Healthcare Conference. Jefferies Virtual Healthcare Conference Date: June 2 – June 4, 2020 Company...

Intec Pharma to Present at Jefferies Virtual Healthcare Conference

JERUSALEM , May  04, 2020  (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 16,291,952 of the Company’s ordinary shares, at a purchase price of $0.30690 per share, in a registered direct offering. Intec has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 8,145,976 ordinary shares. The offering is expected to close on or about May 6, 2020, subject to satisfaction of customary closing conditions.

Intec Pharma Announces $5.0 Million Registered Direct Offering

Arena Pharmaceuticals

Cara Therapeutics

Corbus Pharmaceuticals Holdings

Cronos Group

Greenlane Holdings

GW Pharmaceuticals

Marrone Bio Innovations

New Age Beverages

OrganiGram Holdings Inc.

Psychemedics

SNDL Inc.

Tilray Brands

Therapix Biosciences

Village Farms International

Zynerba Pharmaceuticals

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Top Marijuana Stocks on the NASDAQ

JERUSALEM, Jan.  30, 2020  (GLOBE NEWSWIRE) -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares (which includes pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase up to 16,250,000 ordinary shares, at a public offering price of $0.40 per ordinary share. The warrants have an exercise price of $0.40 per share, are immediately exercisable, and will expire five years from the date of issuance.  In addition, the Company granted the underwriter a 30-day option to purchase up to an additional 2,437,500 ordinary shares and/or warrants to purchase up to 2,437,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The Company expects to receive gross proceeds of $6.5 million from the offering. The offering is expected to close on or about February 4, 2020, subject to customary closing conditions.

Intec Pharma Announces Pricing of $6.5 Million Public Offering

Micro-cap Intec Pharma Ltd (NASDAQ: NTEC) shares are plummeting on heavy volume Monday following a clinical trial readout from the company.

Intec Shares Slammed As Advanced Parkinson's Disease Drug Combo Flunks Late-Stage Study

Shares of biotech Intec Pharma Ltd. plunged 80% in premarket trade Monday after the company said its late-stage trial of a drug meant to treat symptoms of advanced Parkinson's disease did not result in meaningful improvement when compared with standard therapy.

Intec stock plunges 80% after late-stage failure of Parkinson's drug

News for Intec Parent Stock (NTEC)